GBT

Global Blood Therapeutics News

Company Name Stock Ticker Symbol Market Type
Global Blood Therapeutics Inc GBT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 66.84 05:30:58
Open Price Low Price High Price Close Price Prev Close
66.84
more quote information »

Recent News

Date Time Source Heading
8/10/202206:06EDGARAdditional Proxy Soliciting Materials (definitive) (defa14a)
8/09/202208:35TRMNGlobal Blood Therapeutics (GBT) was downgraded to a Hold..
8/08/202217:11EDGARAdditional Proxy Soliciting Materials (definitive) (defa14a)
8/08/202207:29DJNGlobal Blood Therapeutics Shares Rise Premarket After Pfizer..
8/08/202207:07EDGARAdditional Proxy Soliciting Materials (definitive) (defa14a)
8/08/202207:02EDGARQuarterly Report (10-q)
8/08/202206:57EDGARCurrent Report Filing (8-k)
8/08/202206:45GLOBEPfizer to Acquire Global Blood Therapeutics for $5.4 Billion..
8/04/202216:05GLOBEGBT Announces New Employment Inducement Grants
8/03/202218:02EDGARStatement of Changes in Beneficial Ownership (4)
8/03/202218:02EDGARStatement of Changes in Beneficial Ownership (4)
8/03/202218:02EDGARStatement of Changes in Beneficial Ownership (4)
8/03/202218:02EDGARStatement of Changes in Beneficial Ownership (4)
8/03/202218:02EDGARStatement of Changes in Beneficial Ownership (4)
8/03/202218:02EDGARStatement of Changes in Beneficial Ownership (4)
8/03/202217:46EDGARAmended Statement of Beneficial Ownership (3/a)
8/03/202216:05GLOBEGBT Announces Participation at the Wedbush PacGrow..
7/29/202208:00GLOBEGBT to Announce Second Quarter 2022 Financial Results on..
7/26/202203:01GLOBEMHRA Grants Marketing Authorization for GBT’s Oxbryta®..
7/14/202208:00GLOBEGBT Initiates Expanded Access Program for Voxelotor in..
7/13/202208:00GLOBEThe GBT Foundation Awards $250,000 in ACE Grants to Support..
7/08/202222:10TRMNRBC Capital Keeps a Buy Rating on Global Blood Therapeutics..
7/07/202216:05GLOBEGBT Announces New Employment Inducement Grants
7/05/202205:08TRMNWilliam Blair Sticks to Its Buy Rating for Global Blood..
6/29/202212:55TRMNWedbush Reiterates a Buy Rating on Global Blood Therapeutics..
6/29/202208:03EDGARCurrent Report Filing (8-k)
6/29/202208:00GLOBEGBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients..
6/22/202218:01EDGARStatement of Changes in Beneficial Ownership (4)
6/22/202218:00EDGARStatement of Changes in Beneficial Ownership (4)
6/17/202216:05EDGARStatement of Ownership (sc 13g)
6/16/202218:39EDGARStatement of Changes in Beneficial Ownership (4)
6/16/202218:01EDGARStatement of Changes in Beneficial Ownership (4)
6/16/202218:01EDGARStatement of Changes in Beneficial Ownership (4)
6/16/202218:01EDGARStatement of Changes in Beneficial Ownership (4)
6/16/202218:01EDGARStatement of Changes in Beneficial Ownership (4)
6/16/202218:01EDGARStatement of Changes in Beneficial Ownership (4)
6/16/202218:00EDGARStatement of Changes in Beneficial Ownership (4)
6/16/202208:00GLOBENFL Running Back Tevin Coleman and Family Team Up with GBT..
6/13/202208:00GLOBENew GBT Multinational Survey Shines a Needed Light on the..
6/13/202206:45TRMNWedbush Thinks Global Blood Therapeutics’ Stock is Going to..
6/10/202206:10EDGARCurrent Report Filing (8-k)
6/10/202203:00GLOBEGBT Presents Positive New Real-World Evidence Data at..
6/06/202210:00GLOBEThe GBT Foundation Opens 2022 ACCEL Grant Program to Provide..
6/06/202208:00GLOBEGBT’s Inclacumab and GBT601 Receive U.S. FDA Orphan Drug and..
6/03/202217:07EDGARStatement of Changes in Beneficial Ownership (4)
6/02/202216:05GLOBEGBT Announces New Employment Inducement Grants
6/01/202216:05GLOBEGBT to Host Investor Conference Call on Friday, June 10 and..
5/12/202210:00GLOBEGBT Announces Five Data Presentations on Sickle Cell Disease..
5/08/202211:08TRMNSVB Securities Thinks Global Blood Therapeutics’ Stock is..
5/05/202216:05GLOBEGBT Announces Participation in Upcoming Investor Conferences


Your Recent History
NASDAQ
GBT
Global Blo..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now